The National Foundation for Cancer Research is proud to present the Salisbury Award in honor of the Salisbury family’s vision and legacy of funding “high risk, high impact, and high reward” cancer research. Over 80 years of service, the three Salisburys galvanized NFCR into a significant force in cancer research worldwide.
The Salisbury Award encourages and promotes innovative scientists and early stage startups to translate their discoveries into therapies that can improve the lives of cancer patients. The initiative is designed to catalyze and advance promising research innovations onto the path of commercialization. Download the flyer and help spread the word!
NFCR is pleased to be presenting the next Salisbury Award Competition for Entrepreneurial Translational Research, at which prize checks will be provided to the projects judged as with the:
- Highest Potential Impact ($5,000);
- Most Innovative Breakthrough ($3,000); and
- Best Pitch ($2,000).
Additionally, start-ups seeking to commercialize cancer technology associated with the first of these three projects and its team will be introduced to the AIM-HI Accelerator Fund, which was co-founded by NFCR in order to invest in promising early stage oncology companies.
Date:
To Be Determined, Spring 2021
Format:
Virtual, via Zoom
Eligibility:
The Salisbury Award Competition is designed for translational cancer research projects that are formally and verifiably associated with promising scientific discoveries described in the application and that are either within universities, research hospitals, cancer centers, other such laboratories or start-up companies. Submissions by principal investigators of projects with viable clinical trial approval prospects and whose intellectual property has not yet been licensed or acquired by parties outside of the applying institution are especially encouraged.
Format:
A series of private Salisbury Award Competition presentations by individual faculty or non-faculty investigators, scientists at promising early stage start-up companies or designated team members addressing proprietary cancer therapeutic projects*. PowerPoint or similar presentation formats are required. Presenters will be allocated a maximum of 30 minutes, including segue and question and answer periods, which will be strictly enforced per presentation.
Decisions of the Salisbury Award Competition’s Highest Potential Impact, Most Innovative Breakthrough and Best Pitch projects will be made by a judging committee comprised of world-class cancer research, oncology and biomedical industry professionals.
*The Salisbury Award has been designed primarily to help catalyze and raise the profile of cancer therapeutic candidates, although three additional categories too will be considered: diagnostic, preventive vaccine or research platform technologies.
If you have questions, need more information or are interested in sponsoring this or future Salisbury Award Competitions, please contact:
Bradley Gillenwater
NFCR Senior Director for Corporate Outreach & Global Program Development
bgillenwater@nfcr.org
301-961-9161
